COMP <GO>
NNNN vs LLY // ALTMAN Z-SCORE & DEBT/EQUITY
Anbio Biotechnology (Class A) (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: NNNN 3
— LLY 9
■ METRIC PARITY
LAST: $3.72 (-3.12%) • MKT CAP: $535.3M
balance-sheet
—
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
balance-sheet
9.29
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NNNN VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NNNN | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.20% | 83.64% | +3.56 | NNNN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 17.00% | 32.36% | -15.36 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 91.5x | 36.4x | +55.08 | LLY | /valuation <GO> |
| Free Cash Flow Yield | -1.26% | 2.30% | -3.56 | LLY | /fcf-yield <GO> |
| Operating Margin | 66.70% | 40.21% | +26.49 | NNNN | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 31.90% | +36.10 | NNNN | /net-margins <GO> |
| Revenue Growth (YoY) | 5.60% | 45.51% | -39.91 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | — | 9.29 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 29.4 | 66.6 | -37.17 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 77.7x | 26.3x | +51.45 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $535.3M | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NNNN REV | LLY REV | NNNN GROSS % | LLY GROSS % | NNNN FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.6M | $65.18B | 87.2% | 83.0% | -$6.7M | $16.81B |
| FY 2024 | $8.2M | $45.04B | 71.9% | 81.3% | $2.1M | $8.82B |
| FY 2023 | $6.7M | $34.12B | — | 79.3% | $898.4K | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NNNN // BETA —
LLY // BETA 0.51